The Strategy’s health care holdings suffered from a combination of a clinical setback for Vertex Pharmaceuticals (VRTX ... integration and improved mix should help to drive continued margin ...

Clover’s gross margins improved thanks to better product mix and manufacturing efficiency ... While Legacy Minerals, Pure Hydrogen, Trigg Minerals, European Lithium, Vertex Minerals, Island ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Analysts' ratings for Vertex Pharmaceuticals VRTX over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings, showcasing the ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Royal Bank of Canada from $408.00 to $420.00 in a research report sent to investors on Tuesday morning ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ ... helping the company grow product revenue to more than $11 billion in the 2024 full year. It's likely these ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

Vertex Pharmaceuticals saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The company ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 study and ...

Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. Vertex Pharmaceuticals ( NASDAQ:VRTX – Get Free Report ) last announced its quarterly earnings ...